Literature DB >> 24792996

[Stereotactic body radiation therapy and oligometastases].

C Bourgier1, D Azria2, P Fenoglietto3, O Riou4, M-Y Almaghrabi5, S Supiot5, F Mornex6, P Giraud7.   

Abstract

In stage IV cancers, locoregional management of primitive tumours as surgery and/or radiotherapy improved both progression-free survival and overall survival. Among metastatic cancer patients, some of them are considered as oligometastatic stage as they present few metastatic sites associated with low tumor aggressiveness. For those patients, metastatic local control, and therefore prolonged time to progression should be reached through local treatments as surgery and/or radiofrequency ablation and/or stereotactic radiotherapy. Here we propose a review of oligometastatic stage and results from extracranial stereotactic radiotherapy in terms of efficacy and tolerance.
Copyright © 2014 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Extracranial stereotactic irradiation; Oligometastases; Oligométastase; Radiothérapie stéréotaxie extracrânienne

Mesh:

Year:  2014        PMID: 24792996     DOI: 10.1016/j.canrad.2014.02.008

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

1.  SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques.

Authors:  Olivier Riou; Carmen Llacer Moscardo; Pascal Fenoglietto; Emmanuel Deshayes; Raphaël Tetreau; Jessica Molinier; Alexis Lenglet; Eric Assenat; Marc Ychou; Boris Guiu; Norbert Aillères; Ludovic Bedos; David Azria
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-06

2.  Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.

Authors:  Jiahua Lyu; Tao Li; Qifeng Wang; Fang Li; Peng Diao; Li Liu; Churong Li; Jinyi Lang
Journal:  Radiat Oncol       Date:  2018-11-26       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.